A Review of Post-Stroke Cognitive Impairment and the Potential Benefits of Stingless Bee Honey Supplementation.

IF 1.1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Malaysian Journal of Medical Sciences Pub Date : 2024-06-01 Epub Date: 2024-06-27 DOI:10.21315/mjms2024.31.3.5

Nor Liyana Ja'afar, Muzaimi Mustapha, Mahaneem Mohamed, Sabarisah Hashim

{"title":"A Review of Post-Stroke Cognitive Impairment and the Potential Benefits of Stingless Bee Honey Supplementation.","authors":"Nor Liyana Ja'afar, Muzaimi Mustapha, Mahaneem Mohamed, Sabarisah Hashim","doi":"10.21315/mjms2024.31.3.5","DOIUrl":null,"url":null,"abstract":"<p><p>Post-stroke cognitive impairment (PSCI) is a common decline in cognitive abilities that occurs within 3 months after a stroke. During recovery, stroke survivors often experience varying degrees of cognitive decline, with some patients experiencing permanent cognitive deficits. Thus, it is crucial to prioritise recovery and rehabilitation after a stroke to promote optimal protection of and improvement in cognitive function. Honey derived from stingless bees has been linked to various therapeutic properties, including neuroprotective effects. However, scientific evidence for the mechanisms through which these honey supplements enhance cognitive function remains limited. This narrative review aims to provide an overview of the causes of PSCI, current treatments, the biomarkers influencing cognition in post-stroke patients and the potential of stingless bee honey (SBH) as a neuroprotective agent against the progression of PSCI.</p>","PeriodicalId":47388,"journal":{"name":"Malaysian Journal of Medical Sciences","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229577/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaysian Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21315/mjms2024.31.3.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Post-stroke cognitive impairment (PSCI) is a common decline in cognitive abilities that occurs within 3 months after a stroke. During recovery, stroke survivors often experience varying degrees of cognitive decline, with some patients experiencing permanent cognitive deficits. Thus, it is crucial to prioritise recovery and rehabilitation after a stroke to promote optimal protection of and improvement in cognitive function. Honey derived from stingless bees has been linked to various therapeutic properties, including neuroprotective effects. However, scientific evidence for the mechanisms through which these honey supplements enhance cognitive function remains limited. This narrative review aims to provide an overview of the causes of PSCI, current treatments, the biomarkers influencing cognition in post-stroke patients and the potential of stingless bee honey (SBH) as a neuroprotective agent against the progression of PSCI.

查看原文本刊更多论文

中风后认知功能障碍及补充无刺蜂蜂蜜的潜在益处综述》（A Review of Post-Stroke Cognitive Impairment and the Potential Benefits of Stlessing Bee Honey Supplementation）。

脑卒中后认知障碍（PSCI）是脑卒中后 3 个月内出现的一种常见的认知能力下降。在康复过程中，脑卒中幸存者往往会出现不同程度的认知功能下降，有些患者会出现永久性认知功能障碍。因此，在中风后优先进行恢复和康复，以促进认知功能的最佳保护和改善至关重要。从无刺蜜蜂中提取的蜂蜜具有多种治疗特性，包括神经保护作用。然而，有关这些蜂蜜补充剂增强认知功能的机制的科学证据仍然有限。本综述旨在概述脑卒中后认知功能障碍（PSCI）的病因、目前的治疗方法、影响脑卒中后患者认知功能的生物标志物，以及无刺蜂蜂蜜（SBH）作为神经保护剂防止脑卒中后认知功能障碍恶化的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Malaysian Journal of Medical Sciences MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： The Malaysian Journal of Medical Sciences (MJMS) is a peer-reviewed, open-access, fully online journal that is published at least six times a year. The journal’s scope encompasses all aspects of medical sciences including biomedical, allied health, clinical and social sciences. We accept high quality papers from basic to translational research especially from low & middle income countries, as classified by the United Nations & World Bank (https://datahelpdesk.worldbank.org/knowledgebase/ articles/906519), with the aim that published research will benefit back the bottom billion population from these countries. Manuscripts submitted from developed or high income countries to MJMS must contain data and information that will benefit the socio-health and bio-medical sciences of these low and middle income countries. The MJMS editorial board consists of internationally regarded clinicians and scientists from low and middle income countries.